The Promise of Regenerative Medicine Fact vs. Fiction: Oncology, Alzheimer’s, and Beyond

February’s program was held at the Nippon Club. To download the event summary, click here.

According to a report by Allied Market Research, the global regenerative medicine market is expected to grow to US$67.6 billion by 2020, with prominent market share being held by small molecules and biologics with growth also expected in gene and cell therapies.

The immense potential has led to tremendous enthusiasm by patients, healthcare providers, biotech and pharmaceutical companies, investors, governmental bodies, and other stakeholders who see regenerative medicine as the key to dealing with stubborn neurodegenerative diseases like Parkinson’s and Alzheimer’s, as well as chronic inflammatory and degenerative diseases of all types that are becoming increasingly prevalent in globally aging populations. Patient groups see hope in novel treatments for orphan diseases, and big pharma companies see growth potential for new revenue streams.

This program will sort fact from fiction, as experts discuss the current regenerative medicine landscape by talking about the cutting edge research currently taking place, challenges, successes, trends, growth opportunities for investment and partnership, deliverability of regenerative medicine, and the real world evidence backing up some of the “value” of regenerative medicine.

**Click Speaker Name for Bio

John Doyle, DrPH, MPH Senior Vice President, Advisory Services, Quintiles
Dr.Doyle, leads the Values & Outcomes efforts at Quintiles, working with Life Science companies to navigate the transformational changes in the health care marketplace from a population health perspective. As the global health care system migrates from volume to value and outcomes-based medicine, Dr. Doyle’s team of strategists partner with clients to diagnose, strategize, and illuminate a product’s benefit-risk and economic profile tailored to a myriad of market stakeholders to drive health care system performance in an increasingly evidence-based environment. Functional areas of expertise include pricing and reimbursement, health economic and outcomes research (HEOR), and medical affairs. Over the last two decades, Dr. Doyle has authored over 100 abstracts and original research articles in a variety of therapeutic areas, with a  special concentration in oncology. He has lectured for academic and commercial audiences in the U.S., Canada, Europe, Latin America, and Asia. Dr. Doyle received a Bachelor of Science degree in Applied Economics with a concentration in the Life Sciences from Cornell University. He received a Master of Public Health degree and a Doctor of Public Health degree in Epidemiology from the Mailman School of Public Health at Columbia University, where he maintains an adjunct faculty position.
Susan Solomon, Co-founder and CEO, The New York Stem Cell Foundation
Ms. Solomon established the NYSCF, a non-profit organization, in 2005 to accelerate cures through stem cell research. A longtime health-care advocate, Ms. Solomon is a founding member and current President of NYAMR (New Yorkers for the Advancement of Medical Research), is on the Executive and Nominating Committee for the Alliance for Regenerative Medicine, is a member of the Board of Directors of the Regional Plan Association of NY, and she has been a member of the Board of Directors of the Juvenile Diabetes Research Foundation, New York Chapter. Ms. Solomon was also a member of the Strategic Planning Committee of the Empire State Stem Cell Board and is currently on the Board of Directors for the Centre for Commercialization of Regenerative Medicine. In March 2008, Ms. Solomon received a New York State Women of Excellence Award from the Governor of New York. In September 2008, she received the Triumph Award from the Brooke Ellison Foundation for her work in establishing NYSCF and in December 2012, she received the Stem Cell Action Leadership Award from the Genetics Policy Institute.

Prior to founding NYSCF, Ms. Solomon, an attorney, and entrepreneur, spent much of her career building businesses. She established and ran Solomon Partners LLC to provide strategic management consulting to corporations, cultural institutions, foundations and non-profit organizations, and was the founding Chief Executive Officer of She has served as Chairman and Chief Executive Officer of Lancit Media Productions, an Emmy award-winning children’s television production company, and as the President of Sony Worldwide Networks. Ms. Solomon has also held executive positions at MacAndrews and Forbes Holdings and MMG Patricof and Co., and began her career as an attorney with Debevoise & Plimpton.

She received her BA from New York University and her JD from Rutgers University School of Law. She has three sons and is married to Paul Goldberger, the Pulitzer Prize-winning writer on architecture.

Robert Preti, PhD. Vice Chairman, Alliance for Regenerative Medicine, President, PCT, a Caladrius Company
 Dr. Preti is the co-founder of PCT, a Caladrius company, and the visionary behind its successful growth and development strategy over much of the last two decades. He also serves as Chief Technology Officer of Caladrius (formerly NeoStem) where he is involved in assessing and directing the development of Caladrius’ cell therapy pipeline, as well as participating in setting the Company’s strategic direction.

Dr. Preti built PCT to meet a recognized need for high quality manufacturing and development services in an emerging industry. As the cell therapy field has grown, so too has PCT— the company has now served over 120 Clients and performed more than 20,000 cell therapy procedures. His leadership has been instrumental in creating PCT’s Client-focused model that helps bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice. His vision for PCT includes expansion of its manufacturing capacity in the U.S. and Europe, as well as the development of new technological and engineering innovations that will help streamline and automate many cell processing techniques, leading to faster scale up, appropriate cost of goods, and robust quality for the industry.

Before assuming his role at PCT, Dr. Preti held a number of positions within the cellular therapy and blood banking fields. From 1996 to 1999, he was the director of hematopoietic stem cell processing and applied research at Hackensack University Medical Center in Hackensack, N.J. He served in several capacities with the New York Blood Center from 1990 to 1997, including tissue bank director, director of hematopoietic stem cell processing, scientific director, and associate investigator. He also worked as a research scientist for Marrow-Tech Incorporated, which went on to become Advanced Tissue Sciences (ATIS), where work in his laboratory lead to the Dermagraft product currently marketed by Organogenesis.

Dr. Preti began his career in academics, teaching first as an elementary and secondary level educator, then as an adjunct assistant professor and lecturer at Hunter College, an assistant professor at Queensborough Community College, and then an adjunct assistant professor at York College. He also has served as clinical assistant professor of medicine for New York Medical College in Valhalla, N.Y.

Also active in the public health arena, Dr. Preti has served on the Stem Cell Banking Committee and Cord Blood Subcommittee of the New York State Department of Health and on the New Jersey State Department of Health’s Blood Bank Advisory Committee, chairing the Hematopoietic Progenitor Cell Processing Subcommittee. In addition, he has served in a leadership capacity for many professional organizations, including treasurer and founding member of the International Society of Hematotherapy and Graft Engineering, now called ISCT (International Society for Cellular Therapy). He has published and presented extensively on a variety of topics relating to cellular therapies. He recently completed a five year term as a director for AABB, and is currently Vice Chairman for the Alliance for Regenerative Medicine (ARM), where, among other activities, he co-chaired the Standards and Technology Committee.

Dr. Preti holds a Bachelor of Science degree in biology from Fordham University, and a Master of Science degree and Doctorate, both in biology, from New York University